Video

Sangeetha Palakurthi on Strategies for Managing Resistance to Osimertinib in Patients With NSCLC

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non–small cell lung cancer (NSCLC) patient-derived xenografts from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.

Sangeetha Palakurthi, PhD, head of the Cancer Biology and Pharmacology Group at the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, discusses a study that utilized non—small cell lung cancer (NSCLC) patient-derived xenografts (PDXs) from patients on osimertinib (AZD9291) clinical trials to further refine therapeutic strategies.

Researchers have conducted clinical trials looking at biomarker efficacy and combination regimens to better understand patient resistance to osimertinib, Palakurthi explains. This is to help gain a greater understanding of the appropriate treatments for these patients, or to possibly extend durations of response in patients with short-term responses to osimertinib.

Therefore, a platform of NSCLC PDXs was developed in order to refine treatment strategies in these patients, Palakurthi adds.

Related Videos
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Chirag Shah, MD
Jason A. Mouabbi, MD